Cargando…
Abnormalities of mucosal serotonin metabolism and 5‐HT(3) receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron
BACKGROUND: Irritable bowel syndrome with diarrhoea (IBS‐D) is a common condition, greatly reducing the quality of life with few effective treatment options available. AIM: To report the beneficial response shown in our trial with the 5‐hydroyxtryptamine (5‐HT) receptor 3 antagonist, ondansetron in...
Autores principales: | Gunn, David, Garsed, Klara, Lam, Ching, Singh, Gulzar, Lingaya, Melanie, Wahl, Verena, Niesler, Beate, Henry, Amanda, Hall, Ian P., Whorwell, Peter, Spiller, Robin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772086/ https://www.ncbi.nlm.nih.gov/pubmed/31342534 http://dx.doi.org/10.1111/apt.15420 |
Ejemplares similares
-
A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
por: Garsed, Klara, et al.
Publicado: (2014) -
Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit
por: Tooth, David, et al.
Publicado: (2014) -
Randomised clinical trial and meta‐analysis: mesalazine treatment in irritable bowel syndrome—effects on gastrointestinal symptoms and rectal biomarkers of immune activity
por: Castro Tejera, Valeria, et al.
Publicado: (2022) -
Direct healthcare costs of Rome IV or Rome III‐defined irritable bowel syndrome in the United Kingdom
por: Goodoory, Vivek C., et al.
Publicado: (2022) -
Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome
por: Goodoory, Vivek C., et al.
Publicado: (2022)